Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2021 Aug 16;196(1):234–237. doi: 10.1111/bjh.17750

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 British Society for Haematology and John Wiley & Sons Ltd

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

PMC Copyright notice

Fig 2 — A significant proportion of circulating platelets of a vaccine‐induced thrombotic thrombocytopenia (VITT) patients display glycoprotein IIb/IIIa (GPIIb/IIIa) activation [procaspase‐activating compound 1 (PAC‐1) binding], P‐selectin expression and platelet–monocyte aggregate formation, which is revered after treatment with intravenous immunoglobulin (IVIg). Flow cytometry of PAC‐1 binding (upper row), P‐selectin expression (middle row), and platelet–monocyte aggregate formation (lower row) in a patient with VITT. The comparisons show flow cytometry event plots of a healthy control (left column), before IVIg treatment (middle column) and after IVIg treatment (right column).